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SUMMARY
Background
There are plausible mechanisms for how dietary docosahexaenoic acid (DHA), an n3
polyunsaturated fatty acid, could prevent Crohn’s disease (CD).
Aim
To conduct a prospective study to investigate the association between increased intake
of DHA and risk of CD.
Methods
Overall, 229 702 participants were recruited from nine European centres between 1991
and 1998. At recruitment, dietary intakes of DHA and fatty acids were measured using
validated food frequency questionnaires. The cohort was monitored through to June
2004 to identify participants who developed incident CD. In a nested case–control
analysis, each case was matched with four controls; odds ratios (ORs) were calculated
for quintiles of DHA intake, adjusted for total energy intake, smoking, other dietary
fatty acids, dietary vitamin D and body mass index.
Results
Seventy-three participants developed incident CD. All higher quintiles of DHA intake
were inversely associated with development of CD; the highest quintile had the greatest
effect size (OR = 0.07; 95% CI = 0.02–0.81). The OR trend across quintiles of DHA
was 0.54 (95% CI = 0.30–0.99, Ptrend = 0.04). Including BMI in the multivariate analy-
sis, due to its correlation with dietary fat showed similar associations. There were no
associations with the other dietary fatty acids studied.
Conclusion
There were inverse associations, with a biological gradient between increasing dietary
docosahexaenoic acid intakes and incident Crohn’s disease. Further studies in other
populations should measure docosahexaenoic acid to determine if the association is
consistent and the hypothesis tested in randomised controlled trials of purely docosa-
hexaenoic acid supplementation.
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INTRODUCTION
Crohn’s disease (CD) is a chronic inﬂammatory bowel
disease (IBD) of unknown aetiology that can affect any
part of the gastrointestinal tract. Patients often have a
lifelong morbidity from debilitating symptoms, require
surgery and have an increased risk of intestinal failure.
While genomic wide association studies have identiﬁed
over 140 genetic risk loci for CD,1 the risk contribution
from these is estimated to be less than 25%.2 This implies
that other exposures such as environmental/lifestyle
variables, including diet maybe involved in CD aetiology.3
The long chain dietary n3 polyunsaturated fatty
acids (PUFAs), docosahexaenoic acid (DHA) and eico-
sapentaenoic acid (EPA) may be involved in the aetiol-
ogy of CD, given the importance of PUFAs in the
regulation of immunological and inﬂammatory
responses.4 These n3 PUFAs inhibit genes that acti-
vate the inﬂammatory process5 and alter the composi-
tion of cell membranes inﬂuencing lipid raft formation
in cell signalling.6 Furthermore, long chain n3 PUFAs
are metabolised to lipid mediators with weaker
pro-inﬂammatory properties compared to those derived
from n-6 PUFAs.7 More recently, emerging evidence
reports that DHA and EPA can also be metabolised to
lipid mediators with anti-inﬂammatory and inﬂamma-
tion resolving properties.8
Despite the experimental evidence implying biological
plausibility, epidemiological studies investigating associa-
tions between dietary intakes of n3 PUFAs and CD
aetiology are sparse. These are mainly retrospective case–
control studies,9 and a single prospective investigation
which reported the risk of developing CD was unaffected
by total n3 PUFAs and long chain n3 PUFAs
intakes.10 However, the effects of speciﬁc individual long
chain n3 PUFAs, DHA and EPA were not investigated.
This is important as the biological effects of these long
chain n3 PUFAs and their metabolites are not uniform
with them acting via both distinct and shared
pathways.11, 12 Accordingly, we performed this nested
case–control analysis within the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort
investigating the effect of individual long chain n3 PU-
FAs in CD. Demonstrating associations would imply that
the dietary intake of speciﬁc n3 PUFAs should be
measured in future aetiological studies of CD.
METHODS
The methods of the main EPIC cohort study have been
previously described.13 This analysis of CD is a sub-
cohort of 229 702 initially healthy men and women
without CD, aged 20–74 years. Participants were resident
in nine European regions, enrolled between 1991 and
1998 (Table 1). Baseline questionnaires were self-com-
pleted by participants who supplied information on age,
gender, smoking (nonsmoker, ex-smoker or smoker at
recruitment) and diet. Body mass indexes (BMI) were
calculated from participants’ weight and height at base-
line recruitment.14 Habitual diet over the previous year
was measured using validated country-speciﬁc food fre-
quency questionnaires (FFQs) consisting of approxi-
mately 200 food items and nine frequency categories of
intake. Using national databases of food composition,
the daily intakes of total fat, DHA (n3 PUFA), EPA
(n3 PUFA), a-linolenic acid (ALA, n3 PUFA), lino-
leic acid (LA, n-6 PUFA) and oleic acid (OA, n-9 mono-
unsaturated fatty acid, MUFA), total energy intake and
dietary vitamin D were calculated. In all centres, the
FFQs were validated against 24-h recall questionnaires
and biomarkers for speciﬁc nutrients.15 Intakes of ALA
were recorded as this is converted to EPA and DHA.16
LA and OA intakes were recorded as these increase17
and decrease18 arachidonic acid mucosal concentrations,
respectively, which may be involved in the inﬂammatory
process. Dietary vitamin D was recorded as this is found
in similar foods as long chain n3 PUFAs and is associ-
ated with a reduced risk of CD.19
The cohort was monitored after recruitment until June
2004 to identify initially well participants who developed
a new diagnosis of CD. National disease and regional
IBD registries, follow-up questionnaires, in-patient
records and histology databases were used for case iden-
tiﬁcation. Medical notes of potential cases were reviewed
by local gastroenterologists to conﬁrm diagnoses and
acquire information on diagnostic investigations and dis-
ease extent. Cases of indeterminate or microscopic colitis
were excluded. Those with prevalent IBD at recruitment
were excluded, as were participants diagnosed with IBD
<18 months after recruitment, to ensure data reﬂected
diet prior to symptoms and diagnosis.
In a nested case–control analysis, each case was
matched with four randomly selected controls matched
for age at recruitment (6 months), gender, centre and
recruitment date (3 months). Controls had to be alive
on the date of diagnosis of their matched case. None of
the controls had ulcerative colitis, microscopic or inde-
terminate colitis. Intakes of each fatty acid, total energy
and vitamin D were divided into quintiles, according to
the distribution across the cohort. BMI was divided into
four categories (<20 kg/m2, 20–24.9 kg/m2, 25–29.9 kg/m2,
≥30 kg/m2). Baseline characteristics between cases and
Aliment Pharmacol Ther 2014; 39: 834-842 835
ª 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Dietary fatty acids and Crohn’s disease
controls were compared using a t-test for parametric dis-
tributions, a Mann–Whitney test for nonparametric ones
and the v2-test for categorical ones. Odds ratios (OR)
with 95% conﬁdence intervals (CI) were calculated using
conditional logistic regression (STATA version 11) for
total fat, combined long chain n3 PUFAs (DHA and
EPA) and each individual dietary fatty acid and the
development of CD, adjusted for the covariates of ciga-
rette smoking and total energy intake. In a second analy-
sis, total fat and combined long chain n3 PUFAs were
adjusted for individual relevant fatty acids due to their
differing effects on the inﬂammatory process and inter-
dependent metabolism, covariates in the ﬁrst model and
dietary vitamin D. Similar analyses were used to calcu-
late OR for individual dietary fatty acids, adjusting for
the other fatty acids that inﬂuence fatty acid metabolism
and have opposing effects on inﬂammation. A further
analysis included all the covariates from the second
model plus BMI to decrease the risk of residual con-
founding from the likely correlation between dietary fat
and BMI. OR trends were calculated across quintiles
using the score 1–n, with n corresponding to quintiles
1–5 treated as continuous. In a sensitivity analysis, both
the lowest and highest 2.5% of dietary nutrients were
excluded as some participants may under or over report
their intake. A further sensitivity analysis calculated ORs
excluding those who developed CD within 3 years and
5 years after recruitment to assess if fatty acid intake is
related to the time prior to diagnosis. Research protocols
were approved by local ethics committees. All subjects
gave written informed consent for access to their data.
RESULTS
A total of 73 participants developed CD (64% female) at
a median age of 56.4 years (Table 2) with median time
of diagnosis 5.3 years after recruitment. This equates to
an appropriate incidence of 4/100 000 per year based on
the size and follow-up times of each sub-cohort. Of
those with CD, 29% had ileal disease only and 42% had
colonic disease only. Cigarette smoking was positively
associated with CD (OR = 2.40, 95% CI = 1.16–4.94;
P = 0.02). The FFQ data on PUFAs were complete for
100% of cases and 99% of controls, with no signiﬁcant
differences between cases and controls between the med-
ian daily total energy and fatty acids (Table 2).
In the multivariate analysis, no differences were
observed in the odds of CD across quintiles of total fat
or combined long chain n3 PUFAs (DHA and EPA)
Table 1 | Characteristics of the cohorts
Centre
Size of
cohort Nature of cohort
Number of participants
with incident Crohn’s
disease (% of total cases)
Denmark (Aarhus
and Copenhagen)
57 053 Population-based cohort of men and women aged 50–64 years.
Recruited between 1993 and 1997. Cases identiﬁed from national
databases of inﬂammatory bowel disease.
11 (15.1%)
United Kingdom
(Norfolk)
25 639 Population-based cohort of men and women aged 45–74 years.
Recruited between 1993 and 1997. Cases identiﬁed from follow-
up questionnaires, in-patient admission data and histopathology
records.
11 (15.1%)
Germany
(Heidelberg)
25 540 Population-based cohort of men aged 45–65 years and women
aged 35–65 years. Recruited between 1994 and 1998. Cases
identiﬁed from follow-up questionnaires.
9 (12.3%)
Germany
(Potsdam)
27 548 Population-based cohort of men and women, aged 35–64 years.
Recruited between 1994 and 1998. Cases identiﬁed from follow-
up questionnaires.
4 (5.5%)
The Netherlands
(Amsterdam,
Doetinchem,
Maastricht and
Utrecht)
40 092 Men & women, aged 20–70 years recruited between 1993 and
1997 from the general population of three cities (Amsterdam,
Doetinchem & Maastricht) and also the breast cancer
screening programme in Utrecht. Cases identiﬁed from
pathology registries.
17 (23.3%)
Umea (Sweden) 25 732 Population-based cohort of men and women aged 45–69 years.
Recruited between 1991 and 1996. Cases identiﬁed from regional
databases of inﬂammatory bowel disease.
10 (13.7%)
Malm€o (Sweden) 28 098 Population-based cohort of men and women aged 30–60 years.
Recruited between 1992 and 1996. Cases identiﬁed from regional
databases of inﬂammatory bowel disease.
11 (15.1%)
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intake (Table 3). For individual fatty acids, adjusted for
smoking and total energy intake, there were no statisti-
cally signiﬁcant associations across quintiles of dietary
DHA, EPA, LA, ALA or OA, although those for DHA
were all less than one (Table 4). In a second analysis,
including other fatty acids and dietary vitamin D, com-
pared with the lowest quintile, all four of the higher
quintiles of DHA had a reduced odds of CD, with the
greatest reduction in the highest quintile (OR = 0.07,
95% CI = 0.02–0.81). There was a biological gradient
across quintiles of DHA (ORtrend = 0.54, 95%
CI = 0.30–0.99, Ptrend = 0.04). No associations were seen
for other the fatty acids. In particular, not adjusting for
linoleic acid (n-6 PUFA) did not alter the effect sizes in
the multivariate analyses (data not shown). Including
BMI did not materially alter our ﬁndings for DHA
(ORtrend = 0.52, 95% CI = 0.28–0.96, Ptrend = 0.04) or
the other dietary fatty acids. The numbers according to
disease site were small, but the trends across quintiles of
DHA did not show any signiﬁcant associations for ter-
minal ileal or colonic disease. Excluding the lowest 2.5%
and highest 2.5% of all nutrient intakes gave similar
results for the highest quintile of DHA intake
(OR = 0.03, 95% CI = 0.01–0.96) in the model contain-
ing all covariates. The possibility of reverse causation
bias, with symptoms prior to diagnosis inﬂuencing DHA
intake was also considered. However, the magnitude of
the trends across quintiles for DHA were similar in the
third model when excluding those diagnosed within
3 years (ORtrend = 0.49, 95% CI = 0.24–1.04, Ptrend = 0.06)
and within 5 years (ORtrend = 0.37, 95% CI = 0.13–1.07,
Ptrend = 0.07) of recruitment. This process excluded 16
and 32 cases, respectively.
CONCLUSIONS
The main ﬁnding of this study was a statistically signiﬁ-
cant inverse association between the development of
incident CD and the dietary intake of the long chain
n3 PUFA, DHA. The highest quintile of DHA was
associated with a reduction in the odds of developing
incident CD of 94%, the equivalent of eating one to two
portions of oily ﬁsh per week. The data suggest that
long-term DHA intake may be important as the effect
sizes were similar across varying time periods before
diagnosis. Evidences to support a true aetiological associ-
ation with DHA are: plausible biological mechanisms, a
large effect size and a biological gradient with increasing
DHA dietary intakes. Mechanistic studies suggest that
the anti-inﬂammatory properties of DHA may be partly
mediated via competitive inhibition of arachidonic acid
metabolism,20, 21 which is required for the production of
pro-inﬂammatory lipid derived mediators (eicosa-
Table 2 | Characteristics of cases and controls
Controls (n = 292) Cases (n = 73)
Age at recruitment (years, median and range) 50.2 (29.1–75.8) 50.5 (29.4–75.8)
Gender (% female) 64% 64%
Age at diagnosis (years, median and range) – 56.4 (24.0–78.7)
Time between recruitment & diagnosis (years,
median and range)
– 5.3 (1.5–14.3)
Distribution of disease (n, %)
L1, ileal 21 (29%)
L2, colonic 31 (42%)
L3, ileocolonic 14 (19%)
L4, isolated upper GI disease 2 (3%)
Current smoker 27% 40%*
Total energy intake (kJ/day, median and range) 8486 (3684–19 722) 8711 (4509–18 056)
Body mass index (kg/m2) (mean, s.d.) 25.1 (3.7) 25.1 (4.0)
Median daily intakes (g/day, range)
Docosahexaenoic acid 0.13 (0.01–1.49) 0.14 (0.02–0.97)
Eicosapentaenoic acid 0.07 (0.01–0.82) 0.06 (0.01–0.63)
a-linolenic acid 1.30 (0.40–4.51) 1.33 (0.68–5.14)
Linoleic acid 10.33 (3.12–39.71) 10.60 (4.08–44.19)
Oleic acid 21.01 (6.05–76.75) 22.55 (10.18–62.28)
Cases were more likely than controls to be smokers.
* P < 0.05.
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noids).22 These include leukotrienes and prostaglandins
that are present in increased amounts in the mucosa of
patients with CD.23 DHA also inhibits key transcription
factors such as PPARc and NFjΒ, required for the intra-
cellular signalling cascade that activates inﬂammation.5
More recently, studies have reported that DHA is metab-
olised to resolvins, lipid mediators with both anti-inﬂam-
matory and inﬂammation resolving properties. These
may have a role in CD aetiology as resolvins prevent
gastrointestinal inﬂammation in murine models of CD.24
For EPA, the lack of inverse associations, but nonstatisti-
cally signiﬁcant positive ORs were completely unex-
pected, as experimental work has reported that EPA is
metabolised to lipid mediators with similar anti-inﬂam-
matory properties to DHA.25 The reasons for this are
unknown, although hypothetically, the greater range of
dietary intakes for DHA compared to EPA may have
made associations for DHA easier to detect. However,
importantly some studies have reported that EPA is less
effective than DHA in suppressing inﬂammation26 and
may actually be pro-inﬂammatory.27 This may result
from EPA being metabolised to leukotriene B5, which
has weak pro-inﬂammatory activity7 and prostaglandin
E3, which disrupts the intestinal epithelial barrier.
28
Moreover, while one would assume that if DHA and
EPA were present in identical food sources (i.e. oily ﬁsh),
and were predominantly anti-inﬂammatory, then the
directions of the associations for both n3 PUFAs would
be the same. However, that EPA but not DHA is also
present in spreads and cooking oils may also help
explain the discrepancy as both these n3 PUFAs are
not obtained from completely identical sources. Accord-
ingly, the role of these two n3 PUFAs needs to be clar-
iﬁed by following our cohort further to identify more
cases to improve the precision of effect sizes and by
investigating n3 PUFAs in other epidemiological work.
Notably, work on ulcerative colitis in this cohort
reported similar inverse associations between higher die-
tary intakes of DHA, but not EPA.29
The inverse association between DHA and CD was
only observed following adjustment for fatty acids and
vitamin D that could all potentially inﬂuence the biologi-
cal effects of DHA and EPA. Adjustments were per-
formed as the different fatty acids inﬂuence ﬁrstly the
metabolism of each other and secondly the inﬂammatory
pathway itself. As described earlier, dietary ALA is con-
verted to EPA and DHA16 while LA and OA increase17
and decrease18 mucosal arachidonic acid concentrations,
respectively, which is metabolised to pro-inﬂammatory
mediators. The fact that combined long chain n3 PU-
FAs (DHA and EPA) did not affect the odds of CD is
consistent with the only other prospective analysis per-
formed in the exclusively female Nurses’ Health Study
Cohort,10 which did not investigate individual long chain
n3 PUFAs. To the best of our knowledge, our study is
the ﬁrst prospective study of CD investigating DHA and
Table 3 | Dietary fats and the odds of Crohn’s disease
Quintiles, g/day
Controls
(n = 290, %)
Cases
(n = 73, %) OR (95% CI)* OR (95% CI)† OR (95% CI)‡
Total fat
24.4–<55.7 61 (21.0%) 12 (16.4%) 1.00 1.00 1.00
55.7–<68.9 60 (20.7%) 13 (17.8%) 1.18 (0.44–3.13) 1.18 (0.43–3.21) 1.20 (0.43–3.35)
68.9–86.9 59 (20.3%) 13 (17.8%) 1.37 (0.41–4.63) 1.31 (0.38–4.55) 1.40 (0.40–4.97)
87.6–106.7 52 (17.9%) 21 (28.8%) 2.93 (0.82–10.50) 2.68 (0.71–10.10) 2.74 (0.71–10.51)
107.3–221.1 58 (20.0%) 14 (19.2%) 1.59 (0.33–7.59) 1.48 (0.28–7.73) 1.42 (0.26–7.67)
Ptrend = 0.25 Ptrend = 0.32 Ptrend = 0.33
Combined long chain fatty acids (DHA and EPA)
0.01–<0.09 56 (19.3%) 17 (23.3%) 1.00 1.00 1.00
0.09–<0.17 59 (20.4%) 13 (17.8%) 0.65 (0.27–1.57) 0.56 (0.21–1.48) 0.55 (0.21–1.47)
0.17–<0.25 60 (20.8%) 13 (17.8%) 0.64 (0.26–1.57) 0.51 (0.19–1.43) 0.52 (0.19–1.43)
0.26–<0.48 60 (20.8%) 12 (16.4%) 0.66 (0.24–1.80) 0.54 (0.17–1.72) 0.56 (0.18–1.76)
0.48–<2.15 54 (18.7%) 18 (24.7%) 1.19 (0.40–3.57) 1.03 (0.28–3.85) 1.08 (0.29–4.11)
Ptrend = 0.89 Ptrend = 0.84 Ptrend = 0.87
* Adjusted for smoking and total energy intake.
† Covariates in analysis 1 plus dietary vitamin D and relevant fatty acids (total fat unadjusted for individual fatty acids; total
DHA and EPA adjusted for ALA, LA, OA; saturated fat adjusted for DHA, EPA, ALA, LA and OA).
‡ Covariates in analysis 2 and BMI.
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EPA separately, which warrants conﬁrmation in other
populations.
Evidence supporting a beneﬁcial effect of DHA in pre-
venting CD would be provided from randomised con-
trolled trials (RCTs) of DHA supplementation in the
general population investigating if this reduced inci-
dence. Clearly, these are impractical due to the large
number of participants needed to accrue sufﬁcient cases.
DHA in the form of ﬁsh oil supplementation has been
assessed in RCTs of preventing relapse in patients with
CD,30, 31 although subsequent meta-analyses reported lit-
tle beneﬁt.32 This may be as a consequence of n3 PU-
FAs having different roles in CD aetiology compared to
the natural history in patients with established disease.
Alternatively, given that ﬁsh oil supplements contains
both DHA and EPA, which may have different biological
effects, perhaps dietary interventions should focus on
increasing just DHA intake alone.
Our study methodology had several strengths includ-
ing the prospective collection of dietary information
which minimised recall biases. Selection biases were
reduced as cases and controls were drawn from the same
Table 4 | Individual fatty acids and the odds of Crohn’s disease
Dietary fatty acid
intake (quintiles,
g/day)
Controls
(n = 289, %)
Cases
(n = 73, %) OR (95% CI)* OR (95% CI)† OR (95% CI)‡
Docosahexaenoic acid
0.01–<0.07 55 (19.0%) 18 (24.7%) 1.00 1.00 1.00
0.07–<0.12 59 (20.4%) 13 (17.8%) 0.50 (0.20–1.25) 0.35 (0.10–1.26) 0.34 (0.09–1.23)
0.12–<0.17 60 (20.8%) 13 (17.8%) 0.47 (0.18–1.25) 0.22 (0.04–1.13) 0.20 (0.04–1.05)
0.17–<0.30 57 (19.7%) 15 (20.5%) 0.61 (0.22–1.68) 0.16 (0.02–1.12) 0.15 (0.02–1.09)
0.31–<1.49 58 (20.1%) 14 (19.2%) 0.49 (0.15–1.63) 0.07 (0.02–0.81) 0.06 (0.01–0.72)
Ptrend = 0.38 Ptrend = 0.04 Ptrend = 0.04
Eicosapentaenoic acid
0.01–<0.03 55 (19.0%) 18 (24.7%) 1.00 1.00 1.00
0.03–<0.05 60 (20.8%) 12 (16.4%) 0.65 (0.28–1.52) 1.30 (0.42–4.00) 1.38 (0.45–4.26)
0.05–<0.09 61 (21.1%) 12 (16.4%) 0.61 (0.26–1.46) 1.55 (0.38–6.30) 1.62 (0.40–6.72)
0.09–<0.16 58 (20.0%) 14 (19.2%) 0.82 (0.31–2.15) 4.04 (0.66–24.84) 4.42 (0.68–28.70)
0.16–<0.82 55 (19.0%) 17 (23.2%) 1.04 (0.36–2.96) 6.43 (0.72–57.90) 8.56 (0.89–83.82)
Ptrend = 0.99 Ptrend = 0.11 Ptrend = 0.09
a-linolenic acid
0.40–<0.94 59 (20.4%) 14 (19.2%) 1.00 1.00 1.00
0.94–<1.16 60 (20.8%) 12 (16.4%) 0.64 (0.24–1.70) 0.38 (0.12–1.19) 0.41 (0.13–1.30)
1.16–<1.44 54 (18.7%) 19 (26.0%) 1.17 (0.47–2.88) 0.71 (0.24–2.12) 0.76 (0.25–2.30)
1.44–<1.88 59 (20.4%) 13 (17.8%) 0.67 (0.23–1.98) 0.33 (0.08–1.28) 0.32 (0.08–1.30)
1.90–<5.14 57 (19.7%) 15 (20.5%) 0.73 (0.20–2.67) 0.38 (0.07–1.98) 0.40 (0.07–2.09)
Ptrend = 0.85 Ptrend = 0.35 Ptrend = 0.34
Linoleic acid
3.12–<6.93 62 (21.5%) 11 (15.0%) 1.00 1.00 1.00
6.93–<9.41 55 (19.0%) 17 (23.2%) 1.62 (0.67–3.90) 2.42 (0.87–6.77) 2.36 (0.83–6.69)
9.44–<11.35 57 (19.7%) 16 (22.0%) 1.72 (0.65–4.55) 2.47 (0.75–8.11) 2.42 (0.73–8.06)
11.35–<15.03 61 (21.1%) 11 (15.0%) 0.94 (0.32–2.76) 1.39 (0.40–4.84) 1.32 (0.38–4.65)
15.03–<44.20 54 (18.7%) 18 (24.7%) 1.91 (0.67–5.46) 2.34 (0.65–8.42) 2.34 (0.62–8.19)
Ptrend = 0.57 Ptrend = 0.61 Ptrend = 0.66
Oleic acid
6.05–<14.96 61 (21.1%) 12 (16.4%) 1.00 1.00 1.00
14.98–<18.62 58 (20.1%) 14 (19.2%) 1.22 (0.48–3.13) 1.43 (0.51–4.00) 1.29 (0.45–3.67)
18.69–<23.93 58 (20.1%) 15 (20.5%) 1.29 (0.44–3.79) 1.52 (0.43–5.36) 1.61 (0.44–5.89)
24.01–<30.58 55 (19.0%) 17 (23.3%) 1.75 (0.54–5.62) 2.04 (0.51–8.08) 2.04 (0.50–8.34)
30.80–<76.75 57 (19.7%) 15 (20.5%) 1.39 (0.31–6.17) 1.94 (0.35–10.64) 2.04 (0.35–11.87)
Ptrend = 0.49 Ptrend = 0.37 Ptrend = 0.35
* Adjusted for smoking and total energy intake.
† Covariates in analysis 1, the other four dietary fatty acids and dietary vitamin D.
‡ Covariates in analysis 2 and BMI.
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population. We considered the potential confounding
effect of smoking, but had no information on other co-
variates such as family history of CD or appendicectomy.
Residual confounding is a possibility if DHA is a marker
for another, possibly dietary exposure, which is actually
the true aetiological factor. However, including dietary
vitamin D in our models, which is found in similar
foods to longer chain n3 PUFAs, and BMI, did not
change our results. Similarly, the effect sizes were unaf-
fected when adjustments for linoleic acid (n-6 PUFA)
were excluded suggesting that the effects of low DHA
intake were not as a consequence of higher n-6 intakes.
Other aetiological hypotheses will be explored in future
work and DHA adjusted for any associations. Aspects of
our study are generalizable in that our cohort included
both genders recruited from several countries with the
number developing CD approximately similar to that
expected from data in a large European study of IBD
incidence.33 The anatomical distribution of CD is proba-
bly explained by the older age of our cohort as these
patients are more likely to develop colonic disease.34 We
recruited mainly middle aged to elderly participants and
so were unable to ascertain if our ﬁndings apply to
younger people. However, UK studies reporting that
consumption of oily ﬁsh, a marker of DHA intake is up
to 30% lower in those aged 19–64 years, compared to
older people.35 Therefore, the beneﬁts of increasing
DHA intake may be greater in younger persons. A limi-
tation is measurement error inherent in the FFQs for
recording habitual diet. Although FFQs are pragmatic to
use in large epidemiological studies, they are less accu-
rate than either food diaries or weighed records.36 Fur-
thermore, we only had one measure of diet at
recruitment, although it has been reported that diet
remains relatively stable over time in adults in terms of
categories of nutrient intake.37 Both these sources of
measurement error would result in an underestimate
of effect sizes rather than a spurious overestimate. A fur-
ther limitation is the number of CD cases in our study
may mean that smaller dietary associations would be
undetected.
Finally, our statistical analysis, namely adjusting for
all the fatty acids, has both strengths and limitations.
The analysis was an a priori one, which we decided
was important as fatty acids can ﬁrstly inﬂuence the
inﬂammatory process in different ways and secondly
affect the metabolism of each other. Therefore, failure
to consider each one in the analysis could mean effects
went undetected or were spuriously exaggerated.
However, we acknowledge that adjusting for multiple
nutrients can introduce statistical instability leading to
imprecise measures of the effect sizes. Furthermore,
including several factors in a model correlated with
each other, as occurred for DHA and EPA (r = 0.95),
can result in collinearity, although as discussed previ-
ously, there were some differences in the food sources
of these. This phenomenon may introduce spurious
inaccurate estimates of the individual effect sizes,
although the predictivity of the model as a whole
remains accurate. If collinearity is the explanation, then
in our adjusted analysis, this means that the effect of
DHA is dependent on the other fatty acids included.
Despite the possibility of collinearity, evidence for a
true effect of DHA are: a plausible biological mecha-
nism supported by the inverse direction of the associa-
tions, a dose–response effect, and in the model which
excluded other fatty acids, the associations for quintiles
were all in the same direction as the model in which
they were included. Whether the inverse association
with DHA is real, can only be clariﬁed in randomised
controlled trials in participants who are given purely
DHA supplementation. Importantly, additional EPA
should not be administered in view of the suggestive
positive trend we observed and as previous trials of ﬁsh
oil supplementation,31, 32 which contained both DHA
and EPA did not report any clinical beneﬁt.
In conclusion, we report an inverse association
between higher intakes of dietary DHA and the develop-
ment of CD. Evidence for a causal association is sup-
ported by plausible biological mechanisms, large effect
sizes and a possible dose–response relationship. To con-
ﬁrm causality, consistent ﬁndings are needed from other
populations and laboratory studies on potential biological
mechanisms. While appreciating that DHA may play dif-
ferent roles in CD aetiology and treatment, the hypothe-
sis of a protective effect of DHA would be supported by
good quality interventional studies of DHA speciﬁcally
in treating relapses in patients. These trials would assess
the effect of the dose and timing of DHA administered,
compared to appropriate placebos, and would also
remove the potential problem of collinearity which can
exist in observational studies. Such work is important,
for if our ﬁndings are consistent then the incidence of
CD may be reduced by dietary modiﬁcations and inter-
ventions.
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